Oak Investment Partners

ANN ARBOR, Mich., Feb. 6, 2012 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, announced today executive management transitions and Board of Director appointments to strengthen and expand the Company's leadership, as follows: Jeff Riley, a member of the Adeona Board of Directors since March 2010 and Chairman of the Board since November 2011, was appointed as the Company's President and Chief Executive Officer. Scott L. Tarriff and Nelson K. Stacks were appointed independent members of the Company's Board of Directors. James S. Kuo will continue to serve on the Company's Board of Directors, having resigned from his day-to-day management positions to pursue other opportunities. Mr. Riley has stepped down from Adeona's Audit and Nominations Committees; independent director, Jeffrey Kraws, was elected to the Nominations Committee and Mr. Stacks was elected to the ...